# psoriasis - gpt-5.6-luna

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3907
- Completion tokens: 5509
- Reasoning tokens: 
- Total tokens: 9416
- API requests reported: 
- Elapsed seconds: 104.652
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: OpenAI

---
## 1. Overall biological interpretation

The lesional skin transcriptome shows a highly coherent psoriasis-like inflammatory and epidermal remodeling state rather than an isolated single-gene abnormality. The dominant signal combines:

- Strong activation of the **IL-36/IL-20/IL-19 inflammatory cytokine program**
- Marked induction of **epidermal antimicrobial peptides**
- Expansion or activation of **neutrophil/myeloid-associated inflammatory signals**
- Pronounced **keratinocyte hyperproliferation, cornification, and barrier remodeling**
- Additional evidence of **chemokine signaling, immune-cell recruitment, and tissue remodeling**

The extremely small FDR values and large effect sizes indicate that these differences are statistically robust within the analyzed dataset. However, because the input appears to represent bulk lesional skin, the results cannot by themselves distinguish altered transcription within resident keratinocytes from increased abundance of infiltrating immune or vascular cells. They also establish association, not causality.

---

## 2. Core biological programs

### Program 1: IL-36-centered inflammatory cytokine signaling

**Direction:** Upregulated in lesional skin

**Major supporting genes:**  
**IL36A** (+11.37 log2FC), **IL36G** (+5.68), **IL36RN** (+3.01), **IL19** (+7.58), **IL20** (+5.67), **IL26** (+4.36), **TNIP3** (+7.28), **IRAK2** (+2.08), **ZC3H12A** (+3.85)

**Relevant standardized pathways:**

- KEGG **Psoriasis** and **IL-17 signaling**
- Reactome **Cytokine Signaling in Immune System**
- GO **inflammatory response**
- Hallmark **Inflammatory Response**
- Potentially Reactome **NF-κB activation** and interleukin signaling

**Interpretation:**  
The concurrent induction of multiple IL-36-family and IL-20-family cytokines is stronger evidence for an activated cytokine network than would be provided by IL36A alone. IL-36A and IL-36G are typically associated with inflammatory amplification in keratinocytes, whereas IL-19 and IL-20 are linked to epidermal responses and keratinocyte proliferation. The increased expression of **IL36RN**, which encodes the IL-36 receptor antagonist, is consistent with compensatory negative feedback rather than absence of pathway activity. **IRAK2**, **TNIP3**, and **ZC3H12A** further suggest active regulation of innate inflammatory signaling.

**Evidence strength:** Strong direct transcriptomic evidence, supported by pathway biology and established psoriasis literature.

**Limitations:**  
The IL-36 receptor **IL1RL2** is not included in the supplied results, and transcript levels do not demonstrate cytokine secretion, receptor activation, or dependence of the lesion on this pathway. Increased IL36RN may also indicate endogenous counter-regulation. The cytokine signals could partly reflect changes in keratinocyte state or inflammatory-cell composition.

---

### Program 2: Antimicrobial peptide and innate barrier activation

**Direction:** Upregulated

**Major supporting genes:**  
**DEFB4A** (+11.18), **DEFB4B** (+11.03), **DEFB103A** (+5.76), **DEFB103B** (+5.75), **PI3** (+9.24), **S100A7** (+7.09), **S100A7A** (+9.83), **S100A12** (+8.33), **S100A8** (+7.73), **GPR15LG** (+5.52)

**Relevant standardized pathways:**

- GO **antimicrobial humoral response**
- GO **defense response to bacterium**
- Hallmark **Inflammatory Response**
- KEGG **IL-17 signaling**
- Reactome **Antimicrobial peptides**

**Interpretation:**  
The coordinated induction of several beta-defensins, PI3/elafin-related antiprotease activity, and S100-family inflammatory proteins indicates an activated antimicrobial and innate defense state. This is characteristic of psoriatic epidermis and may contribute to altered host–microbe interactions, leukocyte recruitment, and inflammatory amplification. The multiplicity of independent antimicrobial peptide genes makes this a network-level signal rather than a conclusion based on one canonical psoriasis marker.

**Evidence strength:** Very strong direct expression evidence, with concordant ontology/pathway support and extensive disease-association literature.

**Limitations:**  
Antimicrobial peptide induction is not specific to psoriasis and can occur in atopic dermatitis, infection, wounds, and other inflammatory dermatoses. S100A8/A12 may also reflect infiltrating myeloid cells rather than keratinocyte-intrinsic activation. Functional antimicrobial activity cannot be inferred from RNA abundance.

---

### Program 3: Epidermal hyperplasia, cornification, and barrier remodeling

**Direction:** Upregulated

**Major supporting genes:**  
**SPRR2A/B/D/E/F/G** (approximately +3.99 to +7.31), **SPRR3** (+7.18), **LCE3A** (+8.30), **LCE3D** (+5.31), **SERPINB3** (+6.74), **SERPINB4** (+9.12), **SERPINB11** (+4.47), **KRT6A** (+4.30), **GJB2** (+4.42), **GJB6** (+3.02), **S100A7/A7A**, **KLK13**, **PRSS27**

**Relevant standardized pathways:**

- GO **keratinization**
- GO **epidermis development**
- GO **skin development**
- Reactome **Formation of the Cornified Envelope**
- Reactome **Cell–Cell Junction Organization**
- Hallmark **Epithelial–Mesenchymal Transition** is not an ideal primary annotation here and should not be used as the main interpretation without additional mesenchymal markers

**Interpretation:**  
The coordinated increase in small proline-rich proteins, late cornified envelope genes, keratins, serpin family members, connexins, and epidermal proteases indicates substantial remodeling of keratinocyte differentiation and the physical barrier. This pattern is consistent with psoriatic epidermal thickening, altered terminal differentiation, and increased epithelial stress. It also provides a tissue-context explanation for many of the inflammatory genes: activated keratinocytes can produce cytokines, chemokines, and antimicrobial peptides.

**Evidence strength:** Strong direct transcriptomic evidence and strong tissue-specific/pathway evidence.

**Limitations:**  
Bulk tissue expression cannot separate increased expression per keratinocyte from increased representation of particular epidermal layers. Some genes may be markers of differentiation state rather than drivers of disease. Barrier-gene induction does not necessarily imply improved barrier function; psoriatic barrier physiology can remain abnormal despite increased expression of structural proteins.

---

### Program 4: Myeloid/neutrophil-associated inflammation and leukocyte recruitment

**Direction:** Upregulated

**Major supporting genes:**  
**S100A8** (+7.73), **S100A12** (+8.33), **TCN1** (+8.04), **PLBD1** (+2.08), **CXCR2** (+2.70), **GDA** (+5.90), **ADAP2** (+2.09), **TRIM15** (+4.54), **HABP2** (+4.19), **CXCL13** (+5.89)

**Relevant standardized pathways:**

- GO **neutrophil chemotaxis**
- GO **myeloid leukocyte activation**
- Reactome **Neutrophil Degranulation**
- Reactome **Chemokine Receptors Bind Chemokines**
- Hallmark **Inflammatory Response**

**Interpretation:**  
The S100A8/S100A12, TCN1, PLBD1, and myeloid-associated signals are compatible with inflammatory-cell infiltration or activation. **CXCR2** supports a chemotactic environment, while **CXCL13** indicates additional lymphoid-organizing or immune-cell recruitment biology. These findings are consistent with the cellular inflammatory component of psoriatic lesions.

**Evidence strength:** Strong direct dataset evidence for an inflammatory/myeloid-associated state; moderate pathway and disease-literature support.

**Limitations:**  
This program is particularly vulnerable to cell-composition confounding. In bulk skin, increased expression may primarily indicate more neutrophils or other myeloid cells. CXCL13 and CXCR2 should not be interpreted as a direct ligand–receptor pair: CXCL13 classically signals through CXCR5, whereas CXCR2 is associated with other chemokines. Single-cell or spatial data are needed to assign cellular sources.

---

### Program 5: Keratinocyte proliferation and tissue remodeling

**Direction:** Upregulated

**Major supporting genes:**  
**RRM2** (+2.72), **CCNE1** (+2.56), **KRT6A** (+4.30), **TPBG** (+1.86), **WNT5A** (+2.53), **HPSE** (+2.92), **FABP5** (+3.64), **SLC6A14** (+4.47), **CDK5R1** (+2.35)

**Relevant standardized pathways:**

- Hallmark **E2F Targets**
- Hallmark **G2M Checkpoint**
- GO **cell cycle**
- GO **epidermal cell proliferation**
- Reactome **Cell Cycle**
- GO **extracellular matrix organization** or **cell migration** may be relevant to HPSE/WNT5A, but should be treated as secondary without broader matrix evidence

**Interpretation:**  
Increased **CCNE1** and **RRM2** provide direct evidence of cell-cycle activation, while KRT6A and epithelial remodeling genes support an activated, hyperplastic keratinocyte state. **WNT5A**, **HPSE**, and FABP5 are compatible with altered tissue signaling, migration, and metabolic adaptation. Together, these genes fit the histologic hyperplasia of psoriasis.

**Evidence strength:** Moderate-to-strong direct expression evidence, especially for cell-cycle activation; moderate pathway evidence.

**Limitations:**  
Only a limited number of classical cell-cycle genes are present in the supplied subset, so this should not be treated as a complete proliferation signature. Increased cell-cycle transcripts may reflect increased epidermal thickness or altered cell-layer composition rather than a uniform increase in proliferation. Functional proliferation assays are required.

---

## 3. Key genes and interaction modules

The following candidates are prioritized because they are either highly significant, biologically central, or representative of a broader module.

1. **IL36A–IL36G inflammatory module**  
   - **Direction:** Strongly upregulated; IL36A is among the largest effects.  
   - **Role:** Central to inflammatory cytokine signaling and keratinocyte activation.  
   - **Relationship:** IL36A and IL36G are **pathway co-members** and may converge on the same receptor system. Their shared pathway relationship is not evidence of a direct physical interaction. Their expression may also be **co-regulated** by inflammatory transcriptional programs.

2. **IL36RN as an endogenous counter-regulatory component**  
   - **Direction:** Upregulated.  
   - **Role:** Potential negative-feedback component of the IL-36 axis.  
   - **Relationship:** A **regulatory/pathway antagonistic relationship** to IL36A/IL36G signaling is biologically plausible. This is not a direct protein interaction demonstrated by the supplied data.

3. **IL19–IL20 epidermal cytokine module**  
   - **Direction:** Both strongly upregulated.  
   - **Role:** Supports cytokine-mediated keratinocyte activation, proliferation, and barrier remodeling.  
   - **Relationship:** **Pathway co-membership** and potentially shared upstream regulation; direct physical interaction should not be inferred.

4. **DEFB4A/DEFB4B/DEFB103A/DEFB103B antimicrobial module**  
   - **Direction:** Strongly upregulated, especially DEFB4A/B.  
   - **Role:** Antimicrobial defense and inflammatory amplification.  
   - **Relationship:** These genes are **co-members of an antimicrobial peptide program** and may share regulatory control. The dataset does not establish direct peptide–peptide interaction.

5. **S100A8–S100A12 inflammatory module**  
   - **Direction:** Both strongly upregulated.  
   - **Role:** Myeloid-associated inflammation, alarmin activity, and possibly neutrophil recruitment.  
   - **Relationship:** They are known to have potential **direct protein-complex relationships** in relevant inflammatory contexts, but the current table only demonstrates co-upregulation. Their cellular source remains unresolved.

6. **SPRR/LCE/SERPIN cornification module**  
   - **Direction:** Broadly upregulated.  
   - **Role:** Epidermal differentiation, cornified-envelope remodeling, and epithelial stress responses.  
   - **Relationship:** Primarily **pathway co-membership** and shared differentiation regulation, not direct physical interaction.

7. **KRT6A–GJB2/GJB6 epithelial remodeling module**  
   - **Direction:** Upregulated.  
   - **Role:** Activated keratinocyte state, epithelial structure, and intercellular communication.  
   - **Relationship:** GJB2/GJB6 encode connexins that can form gap-junction structures, but the supplied transcript data do not show direct protein assembly. Their relationship to KRT6A is best described as **co-expression and epithelial pathway co-membership**.

8. **CXCL13 immune-recruitment signal**  
   - **Direction:** Upregulated.  
   - **Role:** Possible organization or recruitment of lymphoid cells within inflamed skin.  
   - **Relationship:** A putative ligand relationship with **CXCR5**, not shown in the input. It should not be paired directly with CXCR2 based only on these results. The relationship to CXCR2 is at most **indirect or chemotaxis-related**.

9. **CCNE1–RRM2 proliferation module**  
   - **Direction:** Both upregulated.  
   - **Role:** Cell-cycle entry and DNA synthesis capacity in hyperplastic epidermis.  
   - **Relationship:** **Pathway co-membership** within cell-cycle programs; no direct physical interaction is implied.

10. **CD274/PD-L1 immune-regulatory signal**  
    - **Direction:** Upregulated (+3.44).  
    - **Role:** Could reflect local immune-regulatory adaptation or cytokine-induced expression in lesional skin.  
    - **Relationship:** The relevant interaction is a known **receptor–ligand relationship** with PD-1 on immune cells, but the current data do not establish which cells express CD274 or whether the axis is functionally active.

---

## 4. Validation priorities

### 1. Validate the IL-36 cytokine axis in lesional keratinocytes  
**Classification:** Mechanistic hypothesis; potential therapeutic target

**Why prioritize it:**  
IL36A and IL36G are among the most strongly induced genes, with concurrent IL19, IL20, IL26, IRAK2, and IL36RN induction. This is a multi-gene inflammatory module rather than a single-marker observation.

**Current evidence:**  
Very strong differential expression and pathway coherence.

**External evidence:**  
The IL-36 pathway is well established in inflammatory skin disease and psoriasis biology. However, prior disease association does not prove that it is the dominant driver in this cohort or that pathway inhibition will be clinically effective in all patients.

**Next step:**  
Use lesional tissue immunostaining or spatial transcriptomics to identify cytokine-producing cells; measure protein levels in tissue or ex vivo supernatants; perturb primary keratinocytes or organotypic skin with IL-36 blockade or receptor inhibition.

**Conclusion:** Supported hypothesis, with substantial external biological support; causal dependence remains unestablished.

---

### 2. Determine whether the antimicrobial/myeloid signal reflects keratinocyte activation, infiltrating cells, or both  
**Classification:** Confounding or composition check

**Why prioritize it:**  
DEFB4A/B, DEFB103A/B, PI3, S100A8, and S100A12 are among the strongest signals, but they have different likely cellular sources.

**Current evidence:**  
Strong bulk-tissue induction of antimicrobial and inflammatory genes.

**External evidence:**  
Defensins can be produced by keratinocytes, whereas S100A8/A12 and TCN1 commonly indicate myeloid or neutrophil contributions. These external cell-specific patterns create a plausible composition confounder.

**Next step:**  
Perform single-cell RNA-seq, spatial transcriptomics, or multiplex immunofluorescence using keratinocyte, neutrophil, monocyte, and dendritic-cell markers. Deconvolution should be performed with an appropriate skin reference.

**Conclusion:** Established evidence that the bulk tissue is inflamed; the cellular attribution is an exploratory hypothesis.

---

### 3. Test whether the SPRR/LCE/SERPIN program represents functional barrier remodeling  
**Classification:** Biomarker; mechanistic hypothesis

**Why prioritize it:**  
Many independent epidermal differentiation genes are strongly induced, making this a robust tissue-state signature.

**Current evidence:**  
Broad and highly significant upregulation of SPRR, LCE, SERPINB, KRT6A, GJB2, and GJB6 genes.

**External evidence:**  
These genes are recognized markers of epidermal differentiation and stress. Nevertheless, increased structural-gene expression does not necessarily indicate improved barrier function.

**Next step:**  
Validate protein localization and epidermal-layer distribution by immunohistochemistry; assess transepidermal water loss, lipid composition, tight/gap junction organization, and barrier recovery in lesional versus control tissue.

**Conclusion:** Established as a transcriptomic marker of epidermal remodeling; functional barrier consequences are a supported but unproven hypothesis.

---

### 4. Investigate the relationship between cytokine activation and keratinocyte proliferation  
**Classification:** Interaction / network hypothesis

**Why prioritize it:**  
IL36A/G, IL19/20, KRT6A, CCNE1, and RRM2 together suggest a possible inflammatory-to-hyperplastic circuit.

**Current evidence:**  
Concordant upregulation of inflammatory cytokines, activated keratinocyte markers, and selected cell-cycle genes.

**External evidence:**  
Cytokine signaling can influence keratinocyte proliferation and differentiation, but this relationship is context dependent and may be mediated indirectly through several pathways.

**Next step:**  
Perform ex vivo stimulation of primary keratinocytes with IL-36, IL-19, or IL-20, followed by measurement of proliferation, cell-cycle state, antimicrobial peptides, and barrier genes. Use receptor blockade or genetic perturbation to test pathway dependence.

**Conclusion:** Supported network hypothesis; the current data do not establish directionality or causality.

---

### 5. Evaluate CD274 and CXCL13 as spatially localized immune-state biomarkers  
**Classification:** Biomarker

**Why prioritize it:**  
CD274 and CXCL13 are substantially upregulated but are not sufficient to define a specific immune-cell population from bulk RNA alone.

**Current evidence:**  
CD274 and CXCL13 show strong differential expression in lesional skin.

**External evidence:**  
Both genes can be induced in inflammatory tissues and may be clinically relevant, but their interpretation is highly dependent on cellular source, disease subtype, treatment status, and lesion severity.

**Next step:**  
Confirm protein expression and cellular localization using multiplex immunofluorescence or spatial transcriptomics, then test association with histologic severity, immune-cell abundance, and response to therapy.

**Conclusion:** Exploratory biomarker hypothesis.

---

## 5. Evidence grounding

### Direct evidence from the supplied dataset

- Nearly all highlighted genes have very small FDR values, generally far below conventional significance thresholds.
- Effect sizes are large for IL36A, DEFB4A/B, S100A8/A12, PI3, SPRR genes, SERPINB3/B4, and S100A7/A7A.
- The interpretation is therefore driven by **multi-gene directional concordance**, not by isolated statistical significance.

### Pathway and ontology evidence

- Cytokine, inflammatory, antimicrobial, epidermal differentiation, and cell-cycle annotations provide biologically coherent explanations for the observed gene sets.
- These annotations are not fully independent of one another because many are derived from overlapping gene sets and curated disease literature.

### Protein-interaction and regulatory evidence

- The table itself contains no physical-interaction data, perturbation data, chromatin data, or receptor activation measurements.
- Direct interactions should therefore be restricted to relationships already independently established experimentally, and even then should not be claimed as active in this dataset.
- Most proposed relationships here are pathway co-membership, co-expression, or indirect regulatory hypotheses.

### Disease and tissue evidence

- The expression pattern is highly compatible with known psoriatic lesional skin biology: inflammatory cytokines, antimicrobial peptides, keratinocyte activation, and epidermal hyperplasia.
- This external disease concordance strengthens interpretation but is not independent of pathway annotation when both are based on overlapping published psoriasis studies.

### Genetic, clinical, and therapeutic evidence

- No genetic association, treatment-response, longitudinal, or clinical outcome data were supplied.
- Drug availability or prior therapeutic targeting is not sufficient to infer that any highlighted pathway is an effective therapeutic target in this dataset.
- Therapeutic implications should remain hypothesis-generating until supported by functional or clinical evidence.

---

## 6. Major limitations and alternative explanations

1. **Bulk tissue composition**
   - Increased S100A8, S100A12, TCN1, PLBD1, and related genes may reflect infiltrating neutrophils or other myeloid cells.
   - Investigate with single-cell/spatial profiling, cell-type deconvolution, and multiplex protein localization.

2. **Epidermal-layer and lesion architecture differences**
   - Psoriatic lesions contain altered proportions of basal, suprabasal, and cornified keratinocytes. This can produce large changes in SPRR, LCE, SERPIN, KRT6A, and connexin transcripts without equivalent per-cell transcriptional induction.
   - Investigate by laser-capture microdissection, histology-matched sampling, or spatial transcriptomics.

3. **Association-versus-causation ambiguity**
   - The data identify genes associated with established lesions. They cannot determine whether IL-36, antimicrobial peptides, WNT5A, or proliferation are initiating events, downstream responses, or compensatory adaptations.
   - Perturbation experiments and longitudinal or treatment-response datasets are needed.

4. **Clinical and treatment heterogeneity**
   - Disease severity, lesion chronicity, prior topical/systemic treatment, age, sex, and anatomical site can substantially affect lesional skin expression.
   - Stratified replication and covariate-adjusted analysis are important.

5. **Incomplete statistical context**
   - The table does not provide sample size, confidence intervals, expression distributions, normalization method, batch variables, or validation-cohort performance.
   - Very small P values do not eliminate the possibility of technical or systematic bias; replication in an independent cohort is required.

### Overall conclusion

The strongest and most defensible interpretation is that the lesions exhibit coordinated **IL-36/IL-20 inflammatory activation, antimicrobial defense, epidermal differentiation remodeling, inflammatory-cell involvement, and keratinocyte hyperplasia**. The IL-36-centered inflammatory module and the broad epidermal/antimicrobial signatures are the most compelling findings. The principal unresolved issue is cellular attribution: some signals likely arise from activated keratinocytes, whereas others may primarily reflect infiltrating immune cells.
